ストックスクリーナーアプリを入手
0.00
100.00%
-3.20
アフターアワーズ：
3.17
3.17
+
前日終値:
$3.20
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$75.50M
収益：
$709.00K
当期純損益:
$-43.14M
株価収益率:
0.00
EPS:
-4.54
ネットキャッシュフロー:
$-20.35M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
名前
OncoCyte Corporation
セクター
電話
510-775-0515
住所
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
0.00 | 75.50M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
OncoCyte Corporation (OCX) 最新ニュース
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - MSN
OncoCyte Corporation Crosses 200 Day MA — Signal or NoiseWeekly Profit Analysis & Verified Swing Trading Watchlist - 선데이타임즈
Can OncoCyte Corporation hit a new high this monthWeekly Profit Summary & Verified Swing Trading Watchlist - Newser
Using Bollinger Bands to evaluate OncoCyte CorporationJuly 2025 Selloffs & Weekly Momentum Picks - Newser
Statistical indicators supporting OncoCyte Corporation’s strengthWeekly Stock Analysis & Daily Entry Point Trade Alerts - Newser
Can OncoCyte Corporation recover in the next quarter2025 Market Outlook & Capital Efficient Trade Techniques - Newser
What indicators show strength in OncoCyte CorporationJuly 2025 Institutional & Verified Trade Idea Suggestions - Newser
Is OncoCyte Corporation trending in predictive chart modelsMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Reversal indicators forming on OncoCyte Corporation stockChart-Based Entry Confirmation for Beginners - Newser
Is OncoCyte Corporation reversing from oversold territoryPortfolio Risk Distribution Analysis Tool - Newser
OncoCyte Corporation Stock Chart Analysis: Bullish or Bearish Pattern FormingBond Market & Safe Entry Point Alerts - Newser
Why OncoCyte Corporation stock attracts strong analyst attentionStable Swing Setup with Safety Analysis - Newser
Is OncoCyte Corporation stock overhyped or has real potentialTechnical Long-Term Outlook and Recap Guide - Newser
Combining machine learning predictions for OncoCyte CorporationExpert-Backed High Yield Stock Watchlist - Newser
Top chart patterns to watch in OncoCyte CorporationEarly Buy Opportunity with Chart Triggers - Newser
What MACD and RSI say about OncoCyte CorporationScalable Strategy with Chart Confirmation - Newser
Using economic indicators to assess OncoCyte Corporation potentialFree Accurate Technical Trend Reversal Picks - Newser
Using data filters to optimize entry into Amgen Inc.Entry Optimization Tool with Screener Logic - Newser
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Will a bounce in OncoCyte Corporation offer an exitAlpha Trade Flow With Risk Calibration - Newser
How OncoCyte Corporation stock performs during market volatilityWeekly Entry Signal Based Forecast Tool - Newser
Will OncoCyte Corporation benefit from macro trendsFree Low Risk Equity Screener With Results - Newser
Advanced analytics toolkit walkthrough for OncoCyte CorporationChart Confirmation Setup with ROI Signals - Newser
Detecting support and resistance levels for OncoCyte CorporationInvestment Timeline and ROI Summary Report - Newser
Is It Too Late to Sell OncoCyte CorporationConservative Long Term Growth Plans Under Review - beatles.ru
What to expect from OncoCyte Corporation in the next 30 daysMomentum Entry Alerts with Risk Control - Newser
Is OncoCyte Corporation building a consolidation baseAI-Powered Stock Trend Movement Analysis - Newser
OncoCyte Corporation’s volatility index tracking explainedLong-Term Stock Growth Forecast Insights - Newser
What makes OncoCyte Corporation stock price move sharplyScalable Strategy with Chart Confirmation - Newser
How to build a dashboard for OncoCyte Corporation stock3-Day Market Movement Forecast Analysis - Newser
Should I buy OncoCyte Corporation stock before earningsTrading Volume Spike and Reversal Analysis - Newser
What technical models suggest about OncoCyte Corporation’s comebackBuy/Sell Zone Confirmation Technical Analysis - Newser
OncoCyte Corporation (OCX) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
大文字化:
|
ボリューム (24 時間):